



US011767366B1

(12) **United States Patent**  
**Russell et al.**

(10) **Patent No.:** **US 11,767,366 B1**  
(45) **Date of Patent:** **Sep. 26, 2023**

(54) **PSEUDOTYPED VIRAL PARTICLES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF**

(71) Applicant: **INTERIUS BIOTHERAPEUTICS, INC.**, Philadelphia, PA (US)

(72) Inventors: **Ronnie M. Russell**, Philadelphia, PA (US); **Philip R. Johnson**, Philadelphia, PA (US)

(73) Assignee: **INTERIUS BIOTHERAPEUTICS, INC.**, Philadelphia, PA (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **18/066,420**

(22) Filed: **Dec. 15, 2022**

**Related U.S. Application Data**

(60) Provisional application No. 63/267,039, filed on Jan. 21, 2022, provisional application No. 63/266,044, filed on Dec. 27, 2021, provisional application No. 63/289,977, filed on Dec. 15, 2021, provisional application No. 63/289,888, filed on Dec. 15, 2021.

(51) **Int. Cl.**  
**C12N 15/86** (2006.01)  
**C07K 16/28** (2006.01)  
**C12N 15/113** (2010.01)

(52) **U.S. Cl.**  
CPC ..... **C07K 16/2896** (2013.01); **C12N 15/113** (2013.01); **C12N 15/86** (2013.01); **C12N 2740/15043** (2013.01)

(58) **Field of Classification Search**  
None  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,439,196	A	3/1984	Higuchi
4,447,224	A	5/1984	DeCant, Jr. et al.
4,447,233	A	5/1984	Mayfield
4,487,603	A	12/1984	Harris
4,596,556	A	6/1986	Morrow et al.
4,790,824	A	12/1988	Morrow et al.
4,816,567	A	3/1989	Cabilly et al.
4,941,880	A	7/1990	Burns
4,946,778	A	8/1990	Ladner et al.
5,064,413	A	11/1991	McKinnon et al.
5,260,203	A	11/1993	Ladner et al.
5,312,335	A	5/1994	McKinnon et al.
5,383,851	A	1/1995	McKinnon, Jr. et al.
5,399,163	A	3/1995	Peterson et al.
6,005,079	A	12/1999	Casterman et al.
6,096,002	A	8/2000	Landau
6,620,135	B1	9/2003	Weston et al.
2008/0227736	A1	9/2008	Chen et al.
2018/0371064	A1	12/2018	Fusil et al.
2019/0055568	A1	2/2019	Pulé et al.
2020/0216502	A1	7/2020	Albertini et al.

**FOREIGN PATENT DOCUMENTS**

EP	0404097	B1	12/1990
WO	1988001649	A1	3/1988
WO	1993011161	A1	6/1993
WO	1994004678	A1	3/1994
WO	1994025591	A1	11/1994
WO	2004041862	A2	5/2004
WO	2016065323	A2	4/2016
WO	2020223240	A1	11/2020
WO	2022183072	A1	9/2022

**OTHER PUBLICATIONS**

Albertini et al., "Molecular and Cellular Aspects of Rhabdovirus Entry," *Viruses* (2012) 4:117-129.

Baert et al., "Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease," (2003) *New Engl. J. Med.* 348:601-608.

Beniaminovitz et al., "Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal Antibody," (2000) *New Engl. J. Med.* 342(9):613-619.

Chothia et al., "Canonical Structures for the Hypervariable Regions of Immunoglobulins," (1987) *J. Mol. Biol.* 196:901-917.

Chothia et al., "Conformations of Immunoglobulin Hypervariable Regions," (1989) *Nature* 342: 877-883.

Clackson et al., "Making Antibody Fragments Using Phage Display Libraries," (1991) *Nature* 352:624-628. (Abstract Only).

Finkelshtein et al., "LDL Receptor and its Family Members Serve as the Cellular Receptors for Vesicular Stomatitis Virus," *PNAS* (2013) 110(18): 7306-7311.

Ghosh et al., "Natalizumab for Active Crohn's Disease," (2003) *New Engl. J. Med.* 348:24-32.

Herold et al., "Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus," (2002) *New Engl. J. Med.* 346 (22):1692-1698.

Holliger et al., "Diabodies: Small Bivalent and Bispecific Antibody Fragments," (1993) *Proc. Natl. Acad. Sci. USA* 90: 6444-6448.

Holliger et al., "Engineered Antibody Fragments and the Rise of Single Domains," (2005) *Nat. Biotechnol.* 23(9): 1126-1136.

Hwang et al., "Engineering a Serum-Resistant and Thermostable Vesicular Stomatitis Virus G Glycoprotein for Pseudotyping Retroviral and Lentiviral Vectors," *Gene Ther.* (Aug. 2013) 20(8):807-815.

Kabat, "The Structural Basis for Antibody Complementarity," *Adv. Prot. Chem.* (1978) 32:1-75. (Abstract Only).

(Continued)

*Primary Examiner* — Michael D Burkhardt

(74) *Attorney, Agent, or Firm* — Goodwin Procter LLP

(57) **ABSTRACT**

Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.

**30 Claims. 26 Drawing Sheets**

(56)

**References Cited****OTHER PUBLICATIONS**

Kabat et al., "Unusual Distributions of Amino Acids in Complementarity-Determining (Hypervariable) Segments of Heavy and Light Chains of Immunoglobulins and Their Possible Roles in Specificity of Antibody-Combining Sites," (1977) *J. Biol. Chem.* 252(19):6609-6616.

Lathe, "Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data," *J. Molec. Biol.* (1985) 183:1-12.

Lee et al., "ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells," *Biol. Blood Marrow Transplant* (2019) 25:625-638.

Lipsky et al., "Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis," (2000) *New Engl. J. Med.* 343 (22):1594-1602.

Liu et al., "Chimeric Mouse-Human IgG1 Antibody that can Mediate Lysis of Cancer Cells," *Proc Natl. Acad. Sci., USA* (1987) 84:3439-3443.

Liu et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity," *J. Immunology* (1987) 139(10):3521-3526.

Liu et al., "Randomised, Double Blind, Placebo Controlled Study of Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis Analysed by Area under Disability/Time Curves," *J. Neurol. Neurosurg. Psych.* (1999) 67:451-456.

Marks et al., "By-Passing Immunization," *J. Mol. Biol.* (1991) 222: 581-597.

Milgrom et al., "Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody," *New Engl. J. Med.* (1999) 341:1966-1973.

Muller, "[43] Determination of Affinity and Specificity of Anti-Hapten Antibodies by Competitive Radioimmunoassay," *Meth. Enzymol.* (1983) 92:589-601. (Abstract Only).

Muyldermans et al., "Recognition of Antigens by Single-Domain Antibody Fragments: the Superfluous Luxury of Paired Domains," (2001) *Trends Biochem. Sci.* 26(4):230-235.

Neelapu et al., "Chimeric Antigen Receptor T-Cell Therapy—Assessment and Management of Toxicities," *Nat. Rev. Clin. Oncology* (Jan. 2018) 15(1):47-62.

Nikolic et al., "Structural Basis for the Recognition of LDL-Receptor Family Members by VSV Glycoprotein," *Nature Comm.* (2018) 9(1029):1-12.

Pluckthun, "Antibodies from *Escherichia coli*," *Nature* (Oct. 4, 1990) vol. 347, No. 6292, pp. 497-498.

Portielji et al., "IL-12: A Promising Adjuvant for Cancer Vaccination," *Cancer Immunol. Immunother.* (2003) 52:133-144.

Presta, "Selection, Design, and Engineering of Therapeutic Antibodies," *J. Allergy Clin. Immunol.* (2005) 116 (4):731-736.

Reichmann et al., "Reshaping Human Antibodies for Therapy," *Nature* (1988) 332(6162):323-327.

Roche et al., "Crystal Structure of the Low-pH Form of the Vesicular Stomatitis Virus Glycoprotein G," *Science* (Jul. 14, 2006) 313:187-191.

Roche et al., "Structure of the Prefusion Form of the Vesicular Stomatitis Virus Glycoprotein G," *Science* (Feb. 9, 2007) 315:843-848.

Slamon et al., "Use of Chemotherapy Plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer that Overexpresses HER2," (2001) *New Engl. J. Med.* 344(11):783-792.

Teachey et al., "Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia," *Cancer Discov.* (Jun. 2016) 6(6):664-679.

Tsurushita et al., "Humanization of a Chicken Anti-IL-12 Monoclonal Antibody," *J. Immuno. Methods* (2004) vol. 295, pp. 9-19.

Yang et al., "A Randomized Trial of Bevacizumab, an Anti-Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer," (2003) *New Engl. J. Med.* 349(5):427-434.

International Search Report and Written Opinion for PCT/US2022/081616, dated Jun. 15, 2023, 14 pages.

\* cited by examiner




FIG. 1A




FIG. 1B




FIG. 2A

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.